Clinical Trials Directory

Trials / Completed

CompletedNCT05347602

Gold Factor on Knee Joint Health and Function

A Clinical Study to Evaluate the Safety and Efficacy of Microscopic Doses Oral Administration of Gold Nanoparticles (AuNPs) on Knee Joint Health and Function

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
51 (actual)
Sponsor
4Life Research, LLC · Industry
Sex
All
Age
18 Years – 87 Years
Healthy volunteers
Not accepted

Summary

The purpose of this clinical study was to determine whether gold nanoparticles (AuNP) supplement holds clinical value in improving joint health, function, and quality of life for arthritis patients.

Detailed description

The purpose of this clinical study was to determine whether gold nanoparticles (AuNP) supplement holds clinical value in improving knee joint health, function, and quality of life for arthritis patients. A total of 51 participants were followed for 20 weeks through a three phase longitudinal study. Both subjective and objective parameters were used to measure and monitor changes in knee joint health and function, as well as quality of life.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTGold Factor (Gold Nanoparticles, AuNPs)AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
DIETARY_SUPPLEMENTPlaceboFor the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.

Timeline

Start date
2020-08-03
Primary completion
2020-12-30
Completion
2020-12-30
First posted
2022-04-26
Last updated
2022-07-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05347602. Inclusion in this directory is not an endorsement.